Leprosy Mailing List Blog: March 2024

Thursday, March 28, 2024

Fw: Ref.: (LML) Social exclusion of persons who experience(d) HD

Leprosy Mailing List – March 28, 2024

Ref.: (LML) Social exclusion of persons who experience(d) HD

From: Joel Almeida, India

Dear Pieter and colleagues,

In response to a petition from a former HD (leprosy) patient, The Delhi High Court declared:

"This Court is in agreement with the Petitioner that leprosy affected persons are equal members of our society and discrimination against leprosy affected persons is clear violation of Articles 14 and 21 of the Constitution of India."

Not many diseases require similar declarations from the court. We would certainly wish for HD to be regarded as just another disease. However, it is not yet so. Not many diseases result in people living in "colonies" outside the mainstream. This aspect is not even contemplated by most of the standard scales of socio-economic status. It is a reality for too many people who experience(d) HD.

Likewise, many laws discriminate against people who experience(d) HD, and few if any discriminate against people with other diseases.

India detects over 100,000 new HD cases each year, on average. India also has examples of enlightened legislation, aimed at protecting persons who experience(d) unjust exclusion, negative discrimination, or atrocities.

For example, the Indian HIV & AIDS (Prevention & Control) Act, 2017 requires the written assessment of a qualified and independent healthcare provider competent to do so that such a "protected person" poses a significant risk of transmission of HIV to other persons. Only then is any kind of discrimination tolerated, by law, in India. In HD (leprosy), no such written assessment is required. Instead, even patients who for practical purposes shed no bacilli are too often told that they pose a threat to their contacts.

The experience of other excluded groups could be relevant, in considering remedies. For example, social exclusion of persons belonging to "Scheduled Castes" or "Scheduled Tribes" is an acknowledged challenge in India. These are groups of people who for generations were treated less favourably than others. They are forced too often to live in "colonies" outside the main village or mainstream. Special legislation and special socio-economic schemes have been introduced, aimed at remedying the wrongs. The Protection of Civil Rights Act 1955 and the Prevention of Atrocities Act 1989 are in force. The latter is represented as an Act "to prevent the commission of offences of atrocities against the members of the Scheduled Castes and the Scheduled Tribes, to provide for Special Courts for the trial of such offences and for the relief and rehabilitation of the victims of such offences and for matters connected therewith or incidental thereto." They may be persons like any other, but they have not been treated so. The wrongs are sought to be righted.

Among the many unique challenges faced by people who experience(d) HD, not all are attributable to ignorance among lay persons. Some challenges are attributable to us health professionals. This is usually not intentional. Exposing the diagnosis of HD to others is not exactly respectful of the human right to privacy, confidentiality of diagnosis and a good reputation. Exclusion of anergic HD patients from anti-microbial protection in endemic areas seems inconsistent with their right to adequate medical care. These errors are inconsistent with human rights. They also happen to be unhelpful to stopping transmission.

Human rights are an important determinant of socio-economic status as well as an indicator of socio-economic status. People who experience(d) HD and their families too often have been denied human rights. This need not be glossed over in the course of measuring or describing the socio-economic status of people who experienced HD.

Given that we are interested not merely in describing problems but also in devising and promoting solutions, we could brainstorm about the route to a more just and compassionate world for people who experience(d) HD.

No HD patient need be discriminated against in any way absent a written assessment from a qualified, competent professional that the individual patient poses a significant risk of transmission of HD bacilli to other persons (e.g., based on demonstration of densely packed bacilli in either nasal smears or tissue fluid from abraded skin or at least widely disseminated lesions). In the absence of such objective evidence of infectiousness, an HD patient deserves privacy of diagnosis. No patient with non-infectious forms of HD deserves defamation or an increased risk of social exclusion.

No HD patient with viable bacilli or persistent anergy to HD bacilli need be excluded from anti-microbial protection in endemic areas. Wherever MIP vaccine is available, it can be used to classify highly bacillated patients into responders and non-responders. Else all highly bacillated HD patients in endemic areas can be included in anti-microbial protection even beyond 12 doses of rifampicin. Patients with other diseases are not excluded from effective medical care and protection. There is no need to exclude from anti-microbial protection those HD patients in endemic areas who remain vulnerable to reinfection.

The description of socio-economic status could also draw attention to the drivers of social mobility, given that we desire change. Financial inclusion matters. Land ownership, accumulated savings, access to reasonably priced financial credit are among the important indicators of potential mobility. (1).

Further, Scheduled Castes / Scheduled Tribes seem to hold lessons for HD in India. Their experience shows that highlighting disadvantages can facilitate remedies. Nowadays some people even strive to be classified (misclassified) as SC/ST in the hope of capturing educational or employment opportunities. In countries such as India with a demonstrable willingness to adopt enlightened legislation, acknowledging the problem seems a useful first step to finding solutions.

Unfortunately, people who experience(d) HD are still too often treated less favourably than others. That can change especially if we highlight the social exclusion and denial of human rights that are overlooked by most standard scales of socio-economic status.

Joel Almeida

Tuesday, March 26, 2024

Fw: Ref.: (LML) In Memoriam: Prof. Enrico Nunzi (1941-2024)

Leprosy Mailing List – March 26, 2024

Ref.: (LML) In Memoriam: Prof. Enrico Nunzi (1941-2024)

From: Sunil Deepak, Italy

Dear colleagues,

Prof. Enrico Nunzi, who had dedicated his life to the fight against leprosy and in solidarity with the persons affected with this disease, passed away on 1 March 2024.

Enrico had studied medicine from Padua university in Italy and then specialised in dermatology and tropical dermatology. He had started working at Genoa university hospital in 1976 and had become its professor in 1989. In 2012, after his retirement, he had left for a few years at the Catholic university in Loja (Ecuador) where he had continued to provide occasional support till his last days.

Influenced by a meeting with Raoul Follereau, his work in leprosy started soon after his graduation in medicine when he had worked at Nden leprosarium in Cameroun (1967-68) and then at Kimbau hospital in RD Congo (1971-72). In 1973, after his return from Africa, he had become a part of the medical commission of the Italian Leprosy Association AIFO, and in this role had organised regular international conferences on leprosy during 1970s and 80s, known as the Santa Margherita Ligure leprosy meetings. in 1977-78 he was in Amsterdam with Prof. Dick Leiker, who had then visited the leprosy department in Genoa for a period in the 1980s.

Founder of Italian Hansen Disease Doctors' Association (SIHAN) and Italian Inter-Regional Centre for Leprosy Research (CIRLEP), he had written and edited numerous books and articles including the Handbook of leprosy in 2012 (with Prof. Massone) and the Handbook of Leprosy & Buruli Ulcer in 2022 (with Prof. Massone e Portaels).

I had met Enrico at the International Leprosy Congress in Delhi, India in 1986. Along with professional collaborations, he had been a dear friend and I will miss him.

Dr Sunil Deepak

Italy

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/6ecec5b7-f031-4361-a865-07489fd11c41n%40googlegroups.com.

Fw: Ref.: (LML) Measuring socio-economic status in leprosy-affected communities?

Leprosy Mailing List – March 26, 2024

Ref.: (LML) Measuring socio-economic status in leprosy-affected communities?

From: Wim van Brakel, the Netherlands

Dear Pieter,

I would like to offer one comment on the discussion on SES measurement and the helpful contribution of Mr Sathish Kumar Paul (LML, March 24, 2024). He wrote "However, none of these scales include the leprosy impairments.". Perhaps I misunderstood what he meant by this, but I would propose that, when using SES measures or other measure in rehabilitation, it is very important that they are generic and do not include anything specific on leprosy. The socio-economic problems experienced by persons affected by leprosy are not unique to leprosy. A study on SES should therefore use generic and include a control group that is not affected by leprosy in which the same measure(s) can be used.

Kind regards,

Wim

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/7b269310-6d18-46cd-9af3-4961603e6c2an%40googlegroups.com.

Sunday, March 24, 2024

Fw: (LML) Measuring socio-economic status in leprosy-affected communities?

Leprosy Mailing List – March 24, 2024

Ref.: (LML) Measuring socio-economic status in leprosy-affected communities?

From: Sathish Kumar Paul, India

Dear Pieter,

It is in reference to the mail by Dr. Ruth Butlin, LML, March 20, 2024, we at Schieffelin Institute of Health Research & Leprosy Centre (SIHRLC), Karigiri have been using the Kuppuswamy scale, B G Prasad scale and the Udai Pareekh scales to assess the socio economic status of leprosy affected patients coming to the hospital.

The scales though not specifically designed for leprosy affected individuals have been effective in understanding the socioeconomic status (SES) of the leprosy affected individuals. The Kuppuswamy scale and the B G Prasad scales are regularly updated according to the Consumer Price Index for Industrial Workers(CPI‑IW).

The month‑wise CPI‑IW value was compiled and released by the Labour Bureau under the Ministry of Labour and Employment, Government of India. The Udai Pareek scale includes nine domains of SES, that is Caste, Occupation, House, Land, Education, Social Participation, Farm Power, Material Possessions, and Family Member.

However, none of these scales include the leprosy impairments. We currently at our institute are trying to look for any correlation of the SES scale scores with the leprosy impairments.

Thanks,

Sathish Kumar Paul

SIHRLC Karigiri

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/48519f1f-5cf7-4909-a497-66566b66aa96n%40googlegroups.com.

Friday, March 22, 2024

Fw: Ref.: (LML) Socio-economic status, ostracism and epidemiology of HD

Leprosy Mailing List – March 22, 2024

Ref.: (LML) Socio-economic status, ostracism and epidemiology of HD

From: Joel Almeida, India

Dear Pieter and colleagues,

People who experience(d) HD (leprosy) are disproportionately found in HD "colonies". Not many diseases of mind or body result in such extreme exclusion. Anecdotes of extreme or even criminal cruelty towards persons believed to have HD are not difficult to find.

Even the family members of people who experience(d) HD tend to be treated less favourably than others merely because their address is recognised as being in an HD colony. It does not seem to matter that these family members have no signs of disease and are virtually incapable of transmitting HD bacilli to anyone.

Persons with self-healing forms of HD and zero bacilli in nasal smears are often depicted as dangerous to their contacts. This fear-mongering is contradicted by evidence.

(Figure reproduced from Butlin et al, Lepr Rev (2019) 90, 305–320)

Persons with few or no bacilli seem to have negligible capacity to transmit bacilli to anyone. Anti-microbial treatment often reduces their own risk of permanent nerve damage, but apparently makes little or no difference to the risk of new HD among their household contacts.

The ostracism of persons who experience(d) HD is an important avoidable cause of destitution. Prior destitution might increase the risk of all diseases including HD, but HD itself currently increases the risk of destitution in a way that few if any other diseases do..

Are we opposed to spreading the message that only highly bacillated patients have tens of millions of bacilli in nasal discharges, either before or after MDT (through reinfection)? Is it a bad idea to stop transmission by protecting these few patients with anti-microbials? Is it a ridiculous idea to spare the remaining patients and their families from suspicion?

HD currently seems to require a tailor-made scale of socio-economic status, to capture its extreme social consequences. These consequences persist in too many endemic areas. As more fact-based notions about the epidemiology of HD gain traction, persons with non-infectious forms of HD will face less ostracism, exclusion of highly bacillated patients from anti-microbial protection will be remedied, and transmission will be reduced more rapidly.

Best,

Joel Almeida

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/0ed18bbb-f535-4968-8bc6-d9d1920a7769n%40googlegroups.com.

Fw: Ref.: (LML) Measuring socio-economic status in leprosy-affected communities?

Leprosy Mailing List – March 22, 2024

Ref.: (LML) Measuring socio-economic status in leprosy-affected communities?

From: Zoica Bakirtzief, Brazil

Dear Pieter,

We would be happy to share with Ruth (LML, March 20, 2024) the socioeconomic scale we used in a study in Brazil with leprosy affected communities. It is a validated and used for decades in Brazil to access socioeconomic status of various populations and we found it was relevant to persons affected living in general communities not leprosy hospital or colonies.

Kind regards

Zoica

bakirtzief@gmail.com

Zoica Bakirtzief, Ph.D. Psychology

Northstarregional -Sugar Creek/MRTC

Chaska, MN USA

+1 612 449-7142

Whatsapp: +55 55 99674 8383

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/a98b9411-d0be-4503-ac87-8bc883fbc9ccn%40googlegroups.com.

Thursday, March 21, 2024

Fw: Ref.: (LML) Measuring socio-economic status in leprosy-affected communities?

Leprosy Mailing List – March 21 , 2024

Ref.: (LML) Measuring socio-economic status in leprosy-affected communities?

From: Linda Lehmann, USA

Dear Pieter,

Referring to the request by Ruth Butlin, LML, March 20, 2024, I would advise her to contact Dr. Joseph Chukwu joseph.chukwu@dahw.org or Chinwe Eze chinwe.eze@dahw.org to obtain the questionnaire they used for assessing socio-economic status in their self-care studies in the Enugu area of Nigeria. The tool was not standardize but was reviewed by Eileen Stillwaggon and Larry Sawers.

Unfortunately Eileen Stillwaggon passed away but Larry Sawers lsawers@american.edu may be available to help you develop something or may have a standarized tool.

Sincerely,

Linda F. Lehman

Independent Consultant for Disability Prevention and Rehabilitation in NTDs

WhatsApp and USA Cell phone USA: +1 505 504 8749

lfayelehman@gmail.com

SKYPE: lflehman

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/acbc44f8-7411-4af0-8026-a0ce188ae271n%40googlegroups.com.

Wednesday, March 20, 2024

Fw: Ref.: (LML) New Publications On Cross-Cutting Issues In NTDs. March, 2024

Leprosy Mailing List – March 20, 2024

Ref.: (LML) New Publications On Cross-Cutting Issues In NTDs. March, 2024

From: Roos Geutjes and Josephine Breman-Srivastava, Amsterdam, the Netherlands

Dear colleagues,

The NTD Inclusion Score Card (NISC) tool software has been updated, and an Action Plan Tool Kit (APTK) has been developed that comprises references with guides, tools, and recommendations for addressing identified gaps in inclusion. It is available in English, Portuguese, Spanish, French, and Hindi.

The date, location, and theme of the 2024 Annual NNN Conference have been announced. The conference will be held in Kuala Lumpur, Malaysia, from the 1st to the 3rd of October, 2024. The theme of the Conference is Collaboration for Change to Foster Global Equity and Strengthening Community Engagement in NTDs. Make sure to mark your calendars. We will keep you updated on Twitter and the Newsletter when more information is available. Keep an eye on the News& Events section in future Newsletter editions for any NNN Conference updates!

InfoNTD is now on LinkedIn! We will share News & Events, publications, and practical materials on our LinkedIn page. If you want to be kept informed and inspired by all things NTDs, please follow us. We will remain active on Twitter and will continue to share a monthly Newsletter.

Warm regards,

Roos Geutjes and Josephine Breman-Srivastava

www.InfoNTD.org
info@InfoNTD.org

Practical materials

From pipeline to neglected patients: overcoming challenges in drug discovery for NTDs (Webinar Recording)
The International Society for Neglected Tropical Diseases (ISNTD) . 2024.

Psychological interventions implementation manual: integrating evidence-based psychological interventions into existing services (WHO Manual)
World Health Organization . 2024.

Operational manual on indoor residual spraying: Control of vectors of malaria, Aedes-borne diseases, Chagas disease, leishmaniases and lymphatic filariasis (WHO Operational Manual)
World Health Organization . 2023.

NISC software & Action Plan Toolkit

Have you conducted the NISC assessment? Need more ideas on how to further improve on the gaps in inclusion you have identified?

Look no further! The Action Plan Tool Kit (APTK) is here!!!

It comprises 36 references to established guides, tools, and recommended procedures for addressing identified gaps in inclusion. While extending beyond the NTD field, these resources can be customized to tackle issues within NTD organizations related to the inclusion and meaningful participation of individuals affected by NTDs. Consequently, it functions as a valuable resource for implementing tangible and effective actions toward inclusion across the 7 NISC domains, offering insights into best practices, strategies, and ideas. The APTK can be accessed via www.infontd.org/nisc within each language-specific folder.

Additionally, the NISC software has been updated. Make sure to download the most recent version via www.infontd.org/nisc.

Other new publications

Factors related to willingness to participate in biomedical research on neglected tropical diseases: A systematic review
Raimundo-Silva V, Marques CT, Fonseca JR, et al. PLOS Neglected Tropical Diseases. Public Library of Science (PLoS). 2024; 18 (3) : 1-17.

An Insight into the Success, Challenges, and Future Perspectives of Eliminating Neglected Tropical Disease
Hudu SA, Jimoh AO, Adeshina KA, et al. Scientific African. Elsevier BV. 2024.

Involving patients in drug development for Neglected Tropical Diseases (NTDs): A qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into Target Product Profile development.
Castro M, Erber A, Arana B, et al. PLoS neglected tropical diseases. 2024; 18 (2) : 1-21.

Tenth meeting of the Working Group on Monitoring of Neglected Tropical Diseases Drug Efficacy
World Health Organization . 2024.

Adolescents' Perspective Regarding a Community-Wide Mass Drug Administration Program for Soil-Transmitted Helminths in India.
Aruldas K, Johnson J, Saxena M, et al. The American journal of tropical medicine and hygiene. 2024.

Leprosy and its climate dimension
Goswami S, Yadavar S, Sarah N, et al. The Leprosy Mission Trust India. 2024.

Weekly epidemiological record - 36th meeting of the International Task for Disease Eradication, 5-6 October 2023
World Health Organization . Weekly epidemiological record. 2024; 99 (7) : 69-82.

Exploring the Role of Community Involvement in Reducing the Burden of Schistosomiasis and Other Neglected Tropical Diseases in Malawi: Where are We in the Fight Against Neglected Tropical Diseases?
Lubanga A, Bwanali A, Munthali L, et al. Research and reports in tropical medicine. 2024.

Effectiveness of ivermectin mass drug administration in the control of soil-transmitted helminth infections in endemic populations: a systematic review and meta-analysis
Le B, Clarke NE, Legrand N, et al. Infectious Diseases of Poverty. Springer Science and Business Media LLC. 2024; 13 (1) : 1-15.

Artificial intelligence in parasitic disease control: A paradigm shift in health care
Parija SC, Poddar A. Tropical Parasitology. Medknow. 2024; 14 (1) : 2-7.

Prevalence of trachomatous inflammation-follicular and associated factors among children aged 1-9 years in northeastern Ethiopia
Altaseb T, Lingerew M, Adane M. BMC Pediatrics. Springer Science and Business Media LLC. 2024; 24 (1) : 1-11.

Management of paediatric soil-transmitted helminthiasis in a non-endemic area: experience in a reference international health unit.
Espiau M, Ajanovic S, Zarzuela F, et al. Parasitology research. 2024.

Navigating diagnostic and therapeutic challenges in ocular manifestations of Hansen's disease and trachoma: A narrative review.
Gurnani B, Kaur K, Savla H, et al. Indian journal of ophthalmology. 2024.

The potential role of artificial intelligence in the clinical management of Hansen's disease (leprosy)
Deps PD, Yotsu R, Furriel BCRS, et al. Frontiers in Medicine. Frontiers Media SA. 2024.

Stigma associated with cutaneous leishmaniasis in rural Sri Lanka: development of a conceptual framework.
Nuwangi H, Dikomitis L, Weerakoon K, et al. International health. 2024.

Perceived Social Stigma of Cutaneous Leishmaniasis in Hubuna, Saudi Arabia
Elfaki N, Alzahrani MJ, Abdalla Y, et al. Journal of Multidisciplinary Healthcare. Informa UK Limited. 2024.

Dengue vector habitats in Ouagadougou, Burkina Faso, 2020: an unintended consequence of the installation of public handwashing stations for COVID-19 prevention
Ouédraogo WM, Zanré N, Rose NH, et al. The Lancet Global Health. Elsevier BV. 2024; 12 (2) : e199-e200.

Guinea worm disease inched closer to eradication in 2023
Boisson-Walsh A. The Lancet Infectious Diseases. Elsevier BV. 2024.

The global prevalence of Trichuris trichiura infection in humans (2010-2023): A systematic review and meta-analysis
Behniafar H, Sepidarkish M, Tadi MJ, et al. Journal of Infection and Public Health. Elsevier BV. 2024.

Dialling back 'impact' claims: researchers should not be compelled to make policy claims based on single studies
Bann D, Courtin E, Davies NM, et al. International Journal of Epidemiology. Oxford University Press (OUP). 2023.

[A case for the inclusion of oculocutaneous albinism as a skin-related Neglected Tropical Disease].
Aquaron R, Lund P, Baker C. Medecine tropicale et sante internationale. 2023; 3 (4) : 1-13.

Doença de Chagas: aspectos socioambientais de uma doença neglienciada e a fisiopatologia da cardiopatia chagásica
De Castro AG, Fernandes HBGB. Brazilian Journal of Health Review. South Florida Publishing LLC. 2024; 7 (1) : 7171-7181.

Desafios e inovações na terapêutica de doenças negligenciadas: o papel dos fitoterápicos na busca por soluções eficientes
Dutra ASDS, Dutra RFF, Cruz BILD, et al. Brazilian Journal of Implantology and Health Sciences. Brazilian Journal of Implantology and Health Sciences. 2024; 6 (2) : 1967-1994.

Mass drug administration for neglected tropical disease control and elimination: a systematic review of ethical reasons.
Hoefle-Bénard J, Salloch S. BMJ global health. 2024; 9 (3) : 1-13.

Forging a Future Free from Neglected Tropical Diseases
da Silva Emery F, Chibale K. ACS Medicinal Chemistry Letters. American Chemical Society (ACS). 2024.

Neglected tropical disease vaccines: hookworm, leishmaniasis, and schistosomiasis
Hotez PJ, Bottazzi ME, Kaye PM, et al. Vaccine. Elsevier BV. 2023.

Global Dilemma and Needs Assessment Toward Achieving Sustainable Development Goals in Controlling Leishmaniasis.
Bamorovat M, Sharifi I, Khosravi A, et al. Journal of epidemiology and global health. 2024.

Neglected Tropical Diseases: A Comprehensive Review.
CA J, P V, Kandi V, et al. Cureus. 2024; 16 (2) : 1-10.

Use of Spatial Epidemiology in Neglected Tropical Diseases Control, Elimination and Eradication
Chimfwembe K, Simoonga C, Halwindi H, et al. Neglected Tropical Diseases - Unsolved Debts for the One Health Approach. IntechOpen. 2024.

Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis
Mutono N, Basáñez M, James A, et al. The Lancet Global Health. Elsevier BV. 2024.

Gender considerations in One Health: a framework for researchers
Galiè A, McLeod A, Campbell ZA, et al. Frontiers in Public Health. Frontiers Media SA. 2024.

'We no longer experience the same pain': a cross-sectional study assessing the impact of Heart and Sole Africa's podoconiosis prevention education program
Gebreselassie AF, Shimelash N, Kallon A, et al. Transactions of The Royal Society of Tropical Medicine and Hygiene. Oxford University Press (OUP). 2024.

The effect of contextual factors on a health intervention against podoconiosis in Ethiopia
Engdawork K, Tadele G, Nahar P, et al. Frontiers in Tropical Diseases. Frontiers Media SA. 2024.

'My feet cannot stand on their own': podoconiosis patient healthcare expenditures and income impacts in Rwanda
Schurer JM, Bayisenge U, Hakizimana D, et al. Transactions of The Royal Society of Tropical Medicine and Hygiene. Oxford University Press (OUP). 2024.

Prevalence of depressive symptoms in patients with advanced schistosomiasis in China: A systematic review and meta-analysis
Qi Y, Huang M, Sun H, et al. PLOS Neglected Tropical Diseases. Public Library of Science (PLoS). 2024; 18 (3) : 1-16.

Incorporating an intersectional gender approach to improve access to maternal and child health screening services
Arrivillaga MR, Gold M, Rivera EP, et al. International Journal for Equity in Health. Springer Science and Business Media LLC. 2024; 23 (1) : 1-18.

Capacity of community health centers to treat snakebite envenoming in indigenous territories of the Brazilian Amazon.
Sachett A, Strand E, Serrão-Pinto T, et al. Toxicon : official journal of the International Society on Toxinology. 2024.

Strengthening global snakebite data for WHO's goal for 2030.
Munshi H, Gajbhiye R. Lancet (London, England). 2024; 403 (10430) : 907-908.

Weekly epidemiological record: Monthly report on dracunculiasis cases, January - December 2023
World Health Organization . 2024; 99 (6) : 67-68.

Assessment of Urogenital Schistosomiasis Knowledge, Attitudes and Practices Among Abobo Communities in Gambella Regional State, Southwestern Ethiopia
Mohammed T, Degarege A, Aemero M, et al. Environmental Health Insights. SAGE Publications. 2024.

The One Health Concept.
Pitt S, Gunn A. British journal of biomedical science. 2024.

"We Are Just Supposed to Be an NGO Helping": A Qualitative Case Study of Health Workers' and Volunteers' Perceptions of the Government and Civil Society's Role in Fighting Jiggers in Bungoma County, Kenya
Mørkve ÅW, Sitienei J, Van den Bergh G. Societies. MDPI AG. 2024; 14 (2) : 1-17.

WHO officially recognises Noma as a NTD: suggested global scale countermeasures
Mohapatra RK, Mishra S, Kandi V, et al. International Journal of Surgery Open. Ovid Technologies (Wolters Kluwer Health). 2024.

Accelerating the Control and Elimination of Major Parasitic Diseases in China - On World NTD Day 2024.
Hao Y, Tian T, Zhu Z, et al. China CDC weekly. 2024; 6 (6) : 95-99.

Eliminating Trachoma in Africa: The Importance of Environmental Interventions
Ageed A, Khan M. Cureus. Springer Science and Business Media LLC. 2024.

Health and Economic Growth: Reconciling the Micro and Macro Evidence
Bloom D. E, Canning D, Kotschy R, et al. SSRN.

Pull me - push you? The disparate financing mechanisms of drug research in global health.
Matthey M, Hollis A. Globalization and health. 2024; 20 (1) : 1-8.

Impact with equity: EDCTP and equitable research partnerships
Makanga M, Beattie P, Jajkowicz D, et al. The Lancet Global Health. Elsevier BV. 2024; 12 (4) : e552-e554.

The rising authority and agency of public–private partnerships in global health governance
de Bengy Puyvallée A. Policy and Society. Oxford University Press (OUP). 2024.

Gender and geographical representation at infectious diseases and clinical microbiology conferences
Last K, Hübsch L, Marcelin JR, et al. The Lancet Infectious Diseases. Elsevier BV. 2024; 24 (3) : e153-e154.

News & Events

The 2024 Falcon Awards for Disease Elimination

The Falcon Awards for Disease Elimination is an awards scheme that aims to help partners go further and faster towards their disease elimination goals. This year, GLIDE's third iteration of the Falcon Awards is focusing on accelerating disease elimination in the Western Pacific Region. Eligible applications are those that aim to provide catalytic support to disease elimination efforts for Vector-Borne Diseases, Neglected Tropical Diseases or climate infectious diseases across the region through advocacy campaigns or formative research projects. Submission window for application is 22th March to 29th April, 2024.

RSTMH Early Career Grants

The RSTMH Early Career Grants aims to encourage and support the next generation of tropical medicine and global health professionals by providing their first research grant. The maximum RSTMH Early Career Grant award is £5,000. The Project should take up to one year to be completed and should start within 3 months of receiving funding. The projects can be on any topic related to tropical medicine and global health, from across the research spectrum for example: lab, translation, implementation, and policy. Application Deadline is 22nd of April, 2024 at 12 pm (BST).

African Research Leaders – UKRI

The UK Research and Innovation (UKRI) is calling for applicating for funding to support exceptional early to mid-career African researchers to conduct excellent global health research across sub-Saharan Africa (SSA). UKRI aims to attract and retain exceptionally talented 'rising star' individuals who will lead high quality research on key global health issues pertinent to SSA. Awards will provide support for up to five years and the requested amount should not exceed £750,000 in total. The deadline to apply is the 24th of April, 2024.

Call for Abstracts – HSR2024
November 18-22, 2024; Japan.

The 8th Global Symposium on Health Systems Research will be held in Nagasaki, Japan in 2024. The theme of the Symposium is "Building Just and Sustainable Health Systems: Centring People and Protecting the Planet". Abstract submission deadline for capacity strengthening sessions it is 1st of April, 2024.

Become a GLODERM Mentee

The Mentorship Programme aims to strengthen Mentorship in global health dermatology and increase access to educational opportunities in resource-limited settings worldwide by:

Delivering a unique one-on-one mentorship programme.
Delivering free, high quality dermatology training content for trainees worldwide.

The Mentorship Programme is a year long one-on-one Mentoring Programme that connects mentee applicants from low-resource settings with global health dermatology experts from around the world.

Conference on Neglected Tropical Diseases 2024
October 7-9, 2024, Nairobi; Kenya.

The 1st edition of the Conference on Neglected Tropical Diseases, organized by AME is tentatively scheduled from 7-9 October in Nairobi, Kenya, as a hybrid meeting. The abstract-driven conference proposes a platform to disseminate new advancements, real-world data, implementation challenges, and novel governing models to discuss and generate solutions for cross-cutting topics and ultimately reduce the disease burden and societal impact of NTDs. This proposal supports the progress in foundational pillars of the WHO Roadmap by facilitating evidence-based program implementation, leveraging the cross-cutting approach, and providing a forum to discuss a paradigm shift toward country ownership of elimination programs.

iCHORDS Mentorship Program 2024

The iCHORDS mentorship program aims to provide opportunities for the mentorship of early career researchers, PhD candidates, and young professionals interested in the social and behavioural sciences (e.g. anthropology, sociology, economics, etc.) as they relate to neglected tropical disease (NTD) research and program implementation to support the development of the next generation of NTD professionals. iCHORDS will do this by connecting mentees with experienced mentors in the field of NTDs and the social/behavioural sciences. The program will take place from April 22nd - October 28th, 2024. It is expected that participants will be engaged in the program for the 6-month period. Application deadline is 25th of March, 2024 at 23:59 (EST).

Climate Impacts Awards

Wellcome Foundation has launched its 2024 Climate Impact Awards. They will prioritise funding for research that involves and serves the needs of communities most impacted by the health effects of climate change, and advances stories and narratives that tend to be absent in the media or underrepresented in public discourse. Application deadline is the 3rd of April, 2024.

Wellcome Discovery Awards

The Wellcome Discovery Awards scheme provides funding for established researchers and teams from any discipline who want to pursue bold and creative research ideas to deliver significant shifts in understanding that could improve human life, health and wellbeing. Application deadline is the 16th of April, 2024.

Wellcome Career Development Awards

The Wellcome Career Development scheme provides funding for mid-career researchers from any discipline who have the potential to be international research leaders. They will develop their research capabilities, drive innovative programmes of work and deliver significant shifts in understanding that could improve human life, health and wellbeing. Application deadline is the 11th of April, 2024 at 17:00 (BST).

ESCMID Postgraduate Course - Leprosy: back to the future.
May 20-22, 2024, Bergen, Norway.

ESCMID and ILEP have co-organized Leprosy: back to the future, a 3-day postgraduate training program in Bergen, Norway. The program focuses on medical aspects of leprosy so it is designed mostly for medical practitioners who would benefit from learning or updating on current issues in leprosy, especially new approaches to prevention and discussions about 'Zero Leprosy'. However it may also be of interest to program administrators or managers who are already familiar with leprosy. The registration deadline for general attendance is April 22, 2024.

EDCTP 3 - New tools, technologies and approaches for vector control in sub-Saharan Africa

Proposals under this topic should aim to deliver results that are directed, tailored towards, and contributing to the development and evaluation of tools, technologies and approaches for vector-borne diseases, including vector control and disease management technologies. The Proposal process follows a two-stage model. The deadline dates are 4th of April, 2024 and 17th of September, 2024.

EDCTP 3 - Accelerating development and integration of therapeutics against NTDs in sub-Saharan Africa
Proposals under this topic should aim at supporting activities that contribute to at least two of the expected impacts for this call. Proposals under this topic should aim at delivering results that are contributing to the following expected outcomes:

Accelerate development of therapeutics towards registration to make progress in the control and elimination of NTDs in sub-Saharan Africa;
Improve the understanding of barriers for progression of existing and new therapeutics against NTDs through the R&D pipeline;
Generate evidence-based recommendations on how to better integrate research and innovation in efficient supply chains for NTDs;
Gain a better understanding of different country or region-specific health and research needs, to ensure a better case management of patients with NTDs;

The Proposal process follows a two-stage model. The deadline dates are 4th of April, 2024 and 17th of September, 2024.

GDPR & the InfoNTD newsletter

New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regards to the GDPR, including our privacy statement and mailing list.

InfoNTD sends out monthly e-mails with an overview of recent publications on NTDs and cross-cutting issues. The purpose of this activity is to keep subscribers up to date.

InfoNTD will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else.

You can update your preferences or unsubscribe from this list at any time.

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/leprosymailinglist/59584501-39f9-4b63-be32-37281bd6a6ecn%40googlegroups.com.

Pages

Thursday, March 28, 2024

Tuesday, March 26, 2024

Sunday, March 24, 2024

Friday, March 22, 2024

Thursday, March 21, 2024

Wednesday, March 20, 2024